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ABSTRACT 
Objective: To investigate in vitro anticancer activity of different extracts of bark of Symplocos racemosa against hepatocellular carcinoma. 
Methods: Different successive extracts of Symplocos racemosa bark were prepared using hexane, chloroform, ethyl acetate, n-butanol and water and 
were tested in vitro for cytotoxicity using (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay in rat normal liver cells (BRL-3A) and 
human hepatocellular carcinoma (Hep3B) cells. 
Results: Ethyl acetate and chloroform extract of Symplocos racemosa exhibited cytotoxicity against human hepatocellular carcinoma (Hep3B) cells 
in vitro with IC50
Conclusion: Symplocos racemosa bark extracts showed potential cytotoxic effects on human hepatocellular carcinoma cells. The anticancer activity 
exhibited by ethyl acetate and chloroform extract might be due to presence of phenolics and flavonoid constituents present in the bark. Ethyl 
acetate extract can further be explored for possible cytotoxic activity using in vivo models of liver cancer.  
 value (µg/ml) of 63.45 and 75.55 respectively and not affected the normal liver (BRL-3A) cells. 
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Malignant tumors are the second leading cause of death and hepato 
cellluar carcinoma is the one of the world’s third deadliest cancer with 
very high morbidity and mortality rates and poor prognosis. 
Considering the continuing need for effective anticancer agents, 
medicinal plants play an inexhaustible source of anticancer agents in 
term of both variety and mechanism of action [1, 2]. Epidemiological 
studies revealed that consumption of food and beverages rich in 
polyphenols is associated with low risk of cancer due to presence of 
various phyto constituents. Over 50% of anticancer drugs approved by 
United States Food and Drug Administration have been originated 
from natural resources especially from terrestrial plants [3, 4]. 
Symplocos racemosa Roxb. belongs to a unigeneric family 
Symplocaceae and is a small evergreen tree with the height of 6 to 8.5 
m and diameter of 15 cm. It is found commonly in the plains and hills 
of northern India and other Asian countries up to a height of 1400 m. 
The bark of S. racemosa has many glycosides, terpenoids and 
flavonoids with various pharmacological effects. Ethnobotanical 
literature indicates the utility of the bark in liver, uterine and bowel 
complaints such as diarrhea, dysentery and dropsy. It is also used in 
skin diseases, ear & eye disease, vaginal and menstrual disorders, 
tumors, fever, ulcers and scorpion string bite [5-11]. In Ayurveda 
pittaja arbuda and medoja arbuda tumors are reported to be treated 
with bark of S. racemosa in combination with other drugs [12-13]. 
These references provide the traditional backbone to our preliminary 
objectives to screen the cytotoxic potential of bark of S. racemosa.  
Dulbecco’s Modified Eagle medium (DMEM), Fetal bovine serum 
(FBS), RNase A, ethidium bromide, penicillin and streptomycin 
solution were purchased from Himedia laboratories, Mumbai, India. 
Trypsin and MTT were obtained from Sigma Aldrich, Bangalore 
(India). Dimethyl sulphoxide, other chemicals and solvents used in 
this study were of analytical grade and obtained from Merck 
Limited, Mumbai (India). 
The dried bark material was purchased from the local market of 
district Neemuch (Madhya Pradesh, India) authenticated by 
Pharmanza Herbal Pvt. Ltd. Anand, India (PHPL/HB/060). The dried 
bark material was powdered (250g) and extracted with hexane, 
chloroform, ethyl acetate and n-butanol for 72 h using soxhlet 
apparatus and water extract was prepared using hot extraction 
method. The extracts were cooled at room temperature, filtered and 
evaporated to dryness under reduced pressure in a rotary 
evaporator whereas water extract has been evaporated and dried 
under the hot air oven and used for the further study. 
BRL-3A (normal rat liver cell) and Hep3B (human hepatoma cell) 
cell lines have been obtained from the National Centre for Cell 
Science (NCCS) Pune. The cells were maintained in DMEM 
supplemented with 10 % FBS, penicillin (100 IU/ml), streptomycin 
(100µg/ml) and amphotericin-B (5µg/ml) in a humidified 
atmosphere of 5 % CO2
Both normal and cancer cells were pre incubated at a concentration of 
2 × 10
 at 37 °C. 
6 cells/ml in culture medium for 3 h at 37 °C and 6.5 % CO2 and 
75 % relative humidity. Cells were seeded at a concentration of 5 × 104 
cells/well in 100 µl culture medium and various concentrations of 
different extracts (1000 µg/ml-0.05 µg/ml) and standard were added 
into micro plates (96 flat bottomed tissue culture grade wells). Cell 
cultures were further incubated for 24 h at 37 °C and 6.5 % CO2. The 
supernatants were removed and cell layers were washed with 
phosphate buffer saline and 10 µl of MTT labeling mixture, was added 
to that and incubated further for 4 h in a humidified atmosphere at 37 
°C. 100 µl of DMSO was added to each well and then incubated for the 
period of overnight to dissolve the formazan crystals formed. 
Absorbance of the samples was measured using a microplate enzyme 
linked immunosorbent assay (ELISA) reader at wavelength 570 nm. 
Each extract and control was assayed in triplicate in three 
independent experiments. Cells were observed at different time 
intervals during incubation in the presence of the test item. The effect 
of different extracts and fractions of S. racemosa on the viability of 
normal liver and hepatoma cells were presented as the % of viability 
using following formula. Concentration that inhibits 50 % of cell 
growth was used as a parameter for cytotoxicity. IC50 values have been 
determined from plot of the dose response curve between log of 
compound concentration and percentage growth inhibition. IC50
% viability = (A
 value 
has been derived using curve fitting methods with Graph Pad Prism as 
statistical software (Ver. 5.02). 
570 of treated cells–A570 of blank cells)/(A570 of 
controlled cells–A570 of blank cells) × 100. 
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Percentage cell growth inhibition or percentage cytotoxicity was 
calculated by following formula %cytotoxicity = 100–% cell 
viability [14]. 
In the present study, the cytotoxic effect of different extracts of S. 
racemosa bark was evaluated on human hepatoma cell (Hep3B) and 
normal liver cell (BRL-3A) compared to standard drug doxorubicin 
using MTT assay method after 24 h of treatment. The results 
revealed that amongst all extracts tested, ethyl acetate extract and 
chloroform extract showed potential effectiveness against Hep3B 
cell lines with IC50 value (µg/ml) of 63.45 and 75.55 respectively 
and not affected normal cells BRL-3A (>1000 µg/ml). Moderate 
effectiveness of n-butanol extract against Hep3B cell lines was also 
observed with IC50 111.3µg/ml. Fig. 1 and 2 showed the graphical 
representation of concentration in µg/ml versus % cell inhibition of 
standard doxorubicin and five different extracts of S. racemosa 
against Hep3B and BRL-3A cell lines respectively using MTT assay. 
Table 1 represents the IC50 value of doxorubicin and five different 
extracts of S. racemosa bark against Hep3B cell line.  
 
 
Fig. 1: It shows Graphical representation of concentration 
versus %cell inhibition of standard doxorubicin and five 
different extracts of Symplocos racemosa against Hep3B cell line 




ig. 2: It shows Graphical representation of concentration versus 
% cell inhibition of standard doxorubicin and five different 
extracts of Symplocos racemosa against BRL-3A cell line 
The results are shown as mean±SEM from three independent 
experiments 
 
Different extracts of the bark exhibited diverse activity on cell lines 
and the observed selectivity is a result of sensitivity of the particular 
cell line to the active compounds present in the extract. Among the 
different extracts of S. racemosa bark, ethyl acetate and chloroform 
extract showed cytotoxic potential against human hepatocellular 
carcinoma cells, without affecting adversely to the normal cells. It 
may be due to the presence of phytochemicals such as phenolic 
glycosides, steroids, triterpenoids and flavonoids reportedly found 
present in the bark. In continuation to this research work, further 
investigations are ongoing for fractionation of bioactive extracts of 
the bark and identification of the possible phyto constituents 
responsible for the anticancer activity. This preliminary evaluation 
showing anticancer potential of this drug has provided a platform to 
establish more scientific claims to the traditional report of its use in 
cancer. The phytochemicals with prominent activity may serve as a 
novel therapeutic alternative in the treatment or prevention of 
hepatocellular carcinoma and deserved to be investigated further 
using more specific in vivo models of liver cancer. 
 
Table 1: It shows IC50
Name of extract/standard drug 
 value of doxorubicin and five different 
extracts of S. racemosa against Hep3B cell line 
IC50 value (µg/ml) 
Hexane 1000 
Chloroform 75.55 
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